Peptide / Compound,Regulatory status (US),Studied indication / setting,Population,Route,Dose (as reported),Schedule / duration (as reported),Dilution / reconstitution,Key notes / cautions,Source (URL)
Thymosin alpha 1 (thymalfasin),Not FDA-approved (used/approved in some countries),Sepsis adjunct / immune modulation,Adults with sepsis (clinical trial),SC,1.6 mg,Every 12±2 hours up to 7 days,Not provided here—follow clinical trial protocol or licensed pharmacy,Immune-modulating; trial contexts vary; clinician oversight recommended,https://www.clinicaltrials.gov/study/NCT02867267
Thymosin alpha 1 (thymalfasin),Not FDA-approved (used/approved in some countries),Sepsis trial rationale,Adults with sepsis (study protocol),SC,1.6 mg twice daily,1 week,Not provided here—follow trial/label where available,Trial paper discusses dose selection; not a general recommendation,https://www.bmj.com/content/388/bmj-2024-082583
CJC-1295,Not FDA-approved,GH/IGF-1 stimulation (phase I/II style),Healthy adults,SC,30 or 60 µg/kg (noted as well-tolerated),Single + multiple doses over ~2 weeks (study),Not provided here—product-specific; sterile technique required,GH axis effects; adverse events reported in some contexts,https://academic.oup.com/jcem/article/91/3/799/2843281
CJC-1295,Not FDA-approved,Visceral adiposity in HIV (trial design reported),Adults with HIV-related visceral obesity,SC,Escalating regimens: 60/90/120 µg/kg or 60/120/240 µg/kg,Once-weekly injections; escalation 3 weeks then continuation,Not provided here—trial-specific,Historical trial report; not a dosing guide,https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death
Elamipretide (SS-31),Investigational (not FDA-approved),Heart failure (HFrEF) study design,Patients with HFrEF,SC,4 mg or 40 mg,Once daily for 28 days,Not provided here—device/kit-specific in trials,Investigational drug; use only under clinician/trial oversight,https://peptidesociety.org/_template-monographs-4/
Elamipretide (SS-31),Investigational (not FDA-approved),Long-term safety/tolerability (study description),Trial participants (per registry),SC,40 mg,Once daily (registry description),Not provided here—trial device/kit-specific,Investigational; trial context only,https://www.clinicaltrials.gov/study/NCT03323749
AOD-9604,Not FDA-approved,IV dose-escalation (FDA briefing summary),"Males, BMI 24–30 (study summary)",IV,25 to 400 µg/kg,3 single IV doses with washout (summary),Not provided here—hospital/clinical protocol,Peptide discussed in FDA compounding context; not an approved therapy,https://www.fda.gov/media/183584/download
AOD-9604,Not FDA-approved,Metabolic study (animal model),Obese mice (preclinical),Oral,500 µg/kg,Daily for 19 days,N/A,Preclinical; not directly translatable to humans,https://pubmed.ncbi.nlm.nih.gov/11146367/